Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 12-Month Low – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $16.23 and last traded at $16.23, with a volume of 7070 shares traded. The stock had previously closed at $17.10.

Analyst Upgrades and Downgrades

AAPG has been the topic of several analyst reports. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Trading Up 4.9%

The stock’s 50-day simple moving average is $18.21 and its 200 day simple moving average is $20.80. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. On average, research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, UBS Group AG boosted its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.